ArticleEndocrine-related cancer2014

Obatoclax overcomes resistance to cell death in aggressive thyroid carcinomas by countering Bcl2a1 and Mcl1 overexpression.

Devora Champa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.